Skip to main content
    A

    Alpha Tau Medical Ltd (DRTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.97
    -1.41 (-10.54%)

    Market Cap: $1.24B

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Alpha Tau Medical Ltd (DRTS) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Alpha Tau Medical are Structure Therapeutics Inc. American Depositary Shares (GPCR), Tyra Biosciences (TYRA) and Tourmaline Bio (TRML). By market cap, Alpha Tau Medical ranks 7th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B.

    Peer Comparison

    DRTS's ROIC of -176.9% is below the peer median of -39.6%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Alpha Tau Medical (DRTS)$1.24BN/AN/A0.0%-176.9%0.0%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Tyra Biosciences Inc (TYRA)$1.38BN/AN/A0.0%N/A0.0%0.00%
    Tourmaline Bio Inc. (TRML)$1.23BN/AN/A0.0%N/A0.0%0.00%
    Taysha Gene Therapies Inc (TSHA)$1.34BN/A300.6x0.0%-32.8%171.3%0.00%
    Alto Neuroscience, Inc. (ANRO)$1.18BN/AN/A0.0%-23.5%0.0%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    4D Molecular Therapeutics Inc (FDMT)$689.52MN/A8.5x-208.6%-46.4%4506.0%0.00%
    Immatics NV (IMTX)$972.99MN/A17.7x0.0%N/A33.5%0.00%
    Syndax Pharmaceuticals Inc (SNDX)$850.77MN/A2.8x-72.3%-65.0%81.6%0.00%
    Mineralys Therapeutics, Inc. Common Stock (MLYS)$1.36BN/AN/A0.0%-51.1%0.0%0.00%
    Fortrea Holdings Inc. (FTRE)$1.95B26.0x0.7x-2.6%1.8%-1.4%0.00%
    Verastem Inc (VSTM)$1.03BN/A7.8x-178.4%-110.4%113.6%0.00%
    Peer median$1.28B26.0x8.5x0.0%-39.6%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Alpha Tau Medical, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Tyra Biosciences Inc (TYRA)
    Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes...
    TYRA competitors
    Tourmaline Bio Inc. (TRML)
    Tourmaline Bio Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge cell therapies targeting severe and life-threatening conditions...
    Taysha Gene Therapies Inc (TSHA)
    Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies...
    TSHA competitors
    Alto Neuroscience, Inc. (ANRO)
    Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business.
    ANRO competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    4D Molecular Therapeutics Inc (FDMT)
    4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors.
    FDMT competitors
    Immatics NV (IMTX)
    Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies...
    IMTX competitors
    Syndax Pharmaceuticals Inc (SNDX)
    Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
    SNDX competitors
    Mineralys Therapeutics, Inc. Common Stock (MLYS)
    Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular...
    MLYS competitors
    Fortrea Holdings Inc. (FTRE)
    Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry.
    FTRE competitors
    Verastem Inc (VSTM)
    Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients.
    VSTM competitors

    Frequently Asked Questions About DRTS

    Who are Alpha Tau Medical's main competitors?

    The companies most similar to Alpha Tau Medical include Structure Therapeutics Inc. American Depositary Shares (GPCR), Tyra Biosciences (TYRA), Tourmaline Bio (TRML), Taysha Gene Therapies (TSHA) and Alto Neuroscience (ANRO), listed from the closest match.

    Who is Alpha Tau Medical's biggest competitor?

    Beam Therapeutics (BEAM) is the largest of the similar companies at $2.36B; Structure Therapeutics Inc. American Depositary Shares (GPCR) is the closest match by business profile, size, sector and industry.

    How does DRTS stock compare with its competitors?

    DRTS' net margin is 0.0% against a peer median of 0.0%.

    Which of Alpha Tau Medical's competitors pays a higher dividend?

    Alpha Tau Medical pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Alpha Tau Medical bigger than its competitors?

    No. Alpha Tau Medical is 7th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.